Matthew A. Gonda
Founder at Amytrx Therapeutics, Inc.
Profile
Matthew A.
Gonda is the founder of Amytrx Therapeutics, Inc. He currently serves as an Independent Director at DiscoveryBioMed, Inc. In the past, he served as the Chief Executive Officer of PreMD, Inc. from 2011 to 2013, President & Chief Executive Officer of Genovo, Inc. from 1997 to 1998, President, Chief Executive Officer & Director of TransMolecular, Inc. from 1999 to 2005, Chairman of Altimmune, Inc., and Director of Omnimmune Holdings, Inc. in 2008.
He received his undergraduate degree from the University of Virginia, graduate degree from George Mason University, and doctorate from The Johns Hopkins University.
Matthew A. Gonda active positions
Companies | Position | Start |
---|---|---|
DiscoveryBioMed, Inc.
DiscoveryBioMed, Inc. BiotechnologyHealth Technology DiscoveryBioMed, Inc. provides human cell-based drug discovery services. It provides pilot screening and high-throughput screening services for therapeutic-related bioassays, custom immortalized cell lines and therapeutics discovery for certain failure-to-secrete diseases in humans. The company was founded by Erik M. Schwiebert in October 2007 and is headquartered in Birmingham, AL. | Director/Board Member | - |
Amytrx Therapeutics, Inc.
Amytrx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Amytrx Therapeutics, Inc. developed biological medicines. The company was headquartered in Nashville, TN. | Founder | - |
Former positions of Matthew A. Gonda
Companies | Position | End |
---|---|---|
TransMolecular, Inc.
TransMolecular, Inc. BiotechnologyHealth Technology TransMolecular is an oncology-focused biotechnology company committed to developing novel proprietary drugs to diagnose and treat human diseases using a novel tumor targeting platform called TM601. Their development program to date has explored the therapeutic use of TM601 in cancer and neovascular diseases of the eye, and their lead candidate, TM601 conjugated to the radioactive isotope 131I, has a Special Protocol Agreement (SPA) with the FDA for a pivotal, Phase 3 trial in newly diagnosed glioblastoma multiforme (glioma). TM601 has unique properties of highly specific tumor cell binding and internalization while not affecting normal cells, targeting both primary disease sites and metastases. The interaction of TM601 with a specific protein known to be over-expressed on the surface of tumor cells and vascular endothelium is implicated in these tumor-specific binding properties. Conjugated to an anti-cancer radioactive isotope, TM601 has been successful in human and animal models in demonstrating selective targeting and uptake in a number of different tumor types, and in tumor locations within the central nervous system (CNS) and peripherally. Expanded research confirms that TM601 can deliver a variety of conjugates, creating potential for development of a wide array of anti-cancer therapies. In addition to the tumor targeting capability of TM601, a number of studies have also revealed that TM0601 exerts robust anti-angiogenic effects on vessels associated with neovascular disease. Pursuing this anti-angiogenic potential further, They have also determined the utility of TM601 in animal ophthalmic models. The company is leveraging its platform in strategic collaborations with partners seeking to expand product pipelines, extend product life-cycles for existing anti-tumor compounds, or optimize therapeutic activity of marginally effective or restrictively toxic drugs. | Chief Executive Officer | 2005-03-31 |
Genovo, Inc.
Genovo, Inc. Medical SpecialtiesHealth Technology Part of Innoviva, Inc., Genovo, Inc. is a maker of gene and cell therapy products. The company is based in Sharon Hill, PA. Genovo was acquired by AmpliPhi Biosciences Corp. on September 20, 2000 for $84.53 million. | Chief Executive Officer | 1997-12-31 |
PREMD INC. | Chief Executive Officer | - |
OMNIMMUNE HOLDINGS, INC. | Director/Board Member | - |
Altimmune, Inc. /Old/
Altimmune, Inc. /Old/ Medical/Nursing ServicesHealth Services Altimmune, Inc. develops vaccines and other biological products. The firm offers products for use in companion and commercial livestock, including cats, dogs, horses, swine, poultry and aquaculture. The company was founded by G. Michael Alder and De-chu Tang in 1997 and is headquartered in Gaithersburg, MD. | Chairman | - |
Training of Matthew A. Gonda
The Johns Hopkins University | Doctorate Degree |
University of Virginia | Undergraduate Degree |
George Mason University | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
OMNIMMUNE HOLDINGS, INC. | Health Technology |
Private companies | 6 |
---|---|
Altimmune, Inc. /Old/
Altimmune, Inc. /Old/ Medical/Nursing ServicesHealth Services Altimmune, Inc. develops vaccines and other biological products. The firm offers products for use in companion and commercial livestock, including cats, dogs, horses, swine, poultry and aquaculture. The company was founded by G. Michael Alder and De-chu Tang in 1997 and is headquartered in Gaithersburg, MD. | Health Services |
TransMolecular, Inc.
TransMolecular, Inc. BiotechnologyHealth Technology TransMolecular is an oncology-focused biotechnology company committed to developing novel proprietary drugs to diagnose and treat human diseases using a novel tumor targeting platform called TM601. Their development program to date has explored the therapeutic use of TM601 in cancer and neovascular diseases of the eye, and their lead candidate, TM601 conjugated to the radioactive isotope 131I, has a Special Protocol Agreement (SPA) with the FDA for a pivotal, Phase 3 trial in newly diagnosed glioblastoma multiforme (glioma). TM601 has unique properties of highly specific tumor cell binding and internalization while not affecting normal cells, targeting both primary disease sites and metastases. The interaction of TM601 with a specific protein known to be over-expressed on the surface of tumor cells and vascular endothelium is implicated in these tumor-specific binding properties. Conjugated to an anti-cancer radioactive isotope, TM601 has been successful in human and animal models in demonstrating selective targeting and uptake in a number of different tumor types, and in tumor locations within the central nervous system (CNS) and peripherally. Expanded research confirms that TM601 can deliver a variety of conjugates, creating potential for development of a wide array of anti-cancer therapies. In addition to the tumor targeting capability of TM601, a number of studies have also revealed that TM0601 exerts robust anti-angiogenic effects on vessels associated with neovascular disease. Pursuing this anti-angiogenic potential further, They have also determined the utility of TM601 in animal ophthalmic models. The company is leveraging its platform in strategic collaborations with partners seeking to expand product pipelines, extend product life-cycles for existing anti-tumor compounds, or optimize therapeutic activity of marginally effective or restrictively toxic drugs. | Health Technology |
Genovo, Inc.
Genovo, Inc. Medical SpecialtiesHealth Technology Part of Innoviva, Inc., Genovo, Inc. is a maker of gene and cell therapy products. The company is based in Sharon Hill, PA. Genovo was acquired by AmpliPhi Biosciences Corp. on September 20, 2000 for $84.53 million. | Health Technology |
PreMD, Inc.
PreMD, Inc. Medical SpecialtiesHealth Technology PreMD, Inc. engages in manufacturing and distribution of pharmaceutical products. The company was founded by H. B. Brent Norton on November 9, 1992 and is headquartered in Toronto, Canada. | Health Technology |
DiscoveryBioMed, Inc.
DiscoveryBioMed, Inc. BiotechnologyHealth Technology DiscoveryBioMed, Inc. provides human cell-based drug discovery services. It provides pilot screening and high-throughput screening services for therapeutic-related bioassays, custom immortalized cell lines and therapeutics discovery for certain failure-to-secrete diseases in humans. The company was founded by Erik M. Schwiebert in October 2007 and is headquartered in Birmingham, AL. | Health Technology |
Amytrx Therapeutics, Inc.
Amytrx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Amytrx Therapeutics, Inc. developed biological medicines. The company was headquartered in Nashville, TN. | Health Technology |
- Stock Market
- Insiders
- Matthew A. Gonda